Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Merck : Updates on Consumer Health, New Launches -- Earnings Review

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2018 | 05:25pm CEST

By Sonia Amaral Rohter

Germany's Merck KGaA (MRK.XE) reported fourth-quarter results on Thursday. Here's what we watched:

REVENUE: Sales for the quarter were up 0.5% at 3.85 billion euros ($4.78 billion). Analysts had expected sales of about EUR3.8 billion in the fourth quarter, according to Vara Research's consensus forecast.

EARNINGS: Fourth-quarter net profit was EUR1.01 billion, compared with EUR269 million for the same period last year. Earnings before interest, taxes, depreciation and amortization before one-time items, a key figure for the company, were EUR1.01 billion, down 6.5%. According to a consensus forecast compiled by Vara Research, analysts expected adjusted Ebitda of about EUR994.9 million for the quarter.

WHAT WE WATCHED

UPDATE ON CONSUMER HEALTH: The outcome of a sale of Merck's consumer-health business remains unclear. The CEO said he hopes to close a transaction by year-end, but the annual report--which was also published Thursday--says "a disposal of the Consumer Health business within the next 12 months cannot be regarded as highly likely." The company said it didn't finish evaluating non-binding offers made in December before year-end. Based on the offers, Merck is looking at its strategic options. Analysts at Berenberg said they consider a full divestment less likely, with the annual report suggesting "a partial sale or partnership split by geography could be the more likely scenario."

MAVENCLAD AND BAVENCIO: Merck expects both the multiple sclerosis treatment Mavenclad and the cancer immunotherapy Bavencio to "contribute visibly to sales growth" this year. In 2018, Mavenclad is expected to generate sales "in the high double-digit million range," it said, while Bavencio should yield sales in the "mid double-digit million range." The company still plans to file for Mavenclad's approval in the U.S. this year. Peak sales potential outside the U.S. is between EUR500 million and EUR700 million, CEO Stefan Oschmann said, and U.S. approval should generate significant additional sales, though he declined to quantify.

PERFORMANCE MATERIALS: Weakness in liquid crystals is set to continue in 2018, dragging on the performance-materials division, Merck said. However, 2019 should be the "trough year for profitability" in performance materials, it said. "Consensus currently forecasts the trough in 2018, so this may disappoint, but an actual floor commitment should provide some solace for what is otherwise a significant area of uncertainty for the shares," Berenberg said.

R&D AND LAUNCH COSTS: Merck said both R&D and launch costs would drag on 2018 Ebitda. Underlying R&D costs for the healthcare division are budgeted above 2017, but "actual development will be subject to clinical data outcome of priority projects and prioritization decisions." The company also said preparations for Mavenclad's U.S. launch would drive marketing and selling costs.

Write to Sonia Amaral Rohter at sonia.amaralrohter@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
01:50pMERCK : Makes Major Investment in New Singapore Laboratory
AQ
09/14MERCK : Darmstadt, Germany, Presents Interdisciplinary Cosmetics Research at IFS..
PU
09/13MERCK : Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck K..
AQ
09/13MERCK KGAA : and Pfizer`s combo impresses in first-line treatment of advanced ki..
AQ
09/13MERCK KGAA : - BAVENCIO plus INLYTA Significantly Improved Progression-Free Surv..
AQ
09/11Merck KGaA, Pfizer Sees 'Positive Top-Line Results' in Renal Cell Carcinoma S..
DJ
09/11MERCK : BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Prog..
PU
09/10MERCK : New Application Labs in Philadelphia Enable Close Collaboration
PU
09/06FINDINGS FROM MERCK KGAA BROADEN UND : Review of current peripheral blood and...
AQ
09/06MERCK : Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck K..
AQ
More news
News from SeekingAlpha
09/13YOUR DAILY SCOOP : Foamix Zooms, Pfizer And Merck Report Positive 
09/13YOUR CANCER HIGHLIGHT : A Pfizer-Merck KGaA Collab Bears Fruit In The Competitiv.. 
09/11Pfizer's Bavencio + Inlyta shows treatment benefit in late-stage kidney cance.. 
09/07MERCK KG&A (MKGAY) Presents At Citi's 2018 Global Technology Conference - Sli.. 
08/18YOUR DAILY PHARMA SCOOP : Catalyst Positive, JNJ Succeeds, Blue Chips Support Ti.. 
Financials (€)
Sales 2018 14 489 M
EBIT 2018 2 867 M
Net income 2018 2 254 M
Debt 2018 7 214 M
Yield 2018 1,43%
P/E ratio 2018 17,33
P/E ratio 2019 20,38
EV / Sales 2018 1,28x
EV / Sales 2019 1,09x
Capitalization 11 301 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 98,0 €
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-2.57%13 127
ABBVIE-4.24%144 416
KYOWA HAKKO KIRIN CO LTD-6.44%10 359
JAZZ PHARMACEUTICALS PLC20.26%9 726
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD45.57%7 966
CONVATEC GROUP12.26%5 925